Search

Displaying results 5481 - 5490 of 10000 in total
  1. Drug

    MBX-2044

    go.drugbank.com/drugs/DB05598
    Investigational

    MBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).

  2. Drug

    Cemivameran

    go.drugbank.com/drugs/DB19415
    Approved

    It is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030] … Cemivameran (BNT162b2 Omicron (KP.2)) is COVID-19 mRNA vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage KP.2.

  3. Drug

    Serinus canaria feather

    go.drugbank.com/drugs/DB10857
    Approved

    Canary feather is used in allergenic testing.

  4. Drug

    Coumermycin A1

    go.drugbank.com/drugs/DB13912
    Experimental

    Categories: Topoisomerase II Inhibitors
  5. Drug

    Cilazaprilat

    go.drugbank.com/drugs/DB15565
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Thioctic acid tromethamine

    go.drugbank.com/drugs/DB06253
    Experimental

    A salt of alpha-lipoic acid and tromethamine; may be useful in treating vascular stress in patients with diabetes.

  7. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  8. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

  9. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]

  10. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    Orca-T (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) is a donor-derived allogeneic cell therapy used in matched-donor hematopoietic stem cell transplantation for adults with blood … reconstitution and to improve chronic graft-versus-host disease-free survival, in adults with hematological malignancies.